On Tuesday, Novavax, Inc (NASDAQ: NVAX) was -7.26% drop from the session before settling in for the closing price of $7.99. A 52-week range for NVAX has been $3.81 – $23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 653.01% over the past five years. When this article was written, the company’s average yearly earnings per share was at 75.51%. With a float of $146.14 million, this company’s outstanding shares have now reached $160.15 million.
Let’s look at the performance matrix of the company that is accounted for 1543 employees. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.
Novavax, Inc (NVAX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 8.77%, while institutional ownership is 60.02%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.
Novavax, Inc (NVAX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.51% per share during the next fiscal year.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.26, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach 0.27 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Novavax, Inc (NASDAQ: NVAX) saw its 5-day average volume 5.51 million, a positive change from its year-to-date volume of 4.44 million. As of the previous 9 days, the stock’s Stochastic %D was 24.14%. Additionally, its Average True Range was 0.52.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 7.13%, which indicates a significant decrease from 8.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.94% in the past 14 days, which was lower than the 75.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.66, while its 200-day Moving Average is $11.34. Nevertheless, the first resistance level for the watch stands at $7.80 in the near term. At $8.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.46. If the price goes on to break the first support level at $7.14, it is likely to go to the next support level at $6.87. The third support level lies at $6.48 if the price breaches the second support level.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are 160,185K outstanding shares of the company, which has a market capitalization of 1.19 billion. As of now, sales total 983,710 K while income totals -545,060 K. Its latest quarter income was 84,510 K while its last quarter net income were -121,300 K.
